

# Shinsuke Uchikawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3132093/publications.pdf>

Version: 2024-02-01

46  
papers

596  
citations

623574

14  
h-index

677027

22  
g-index

47  
all docs

47  
docs citations

47  
times ranked

828  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
2	The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675.	1.1	4
3	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	1.4	5
4	Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the <i>ATP8B1</i> Gene. <i>Case Reports in Gastroenterology</i> , 2022, 16, 110-115.	0.3	1
5	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340.	4.2	5
6	The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 443-450.	0.6	2
7	Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
8	A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death. <i>Acta Hepatologica Japonica</i> , 2022, 63, 279-285.	0.0	0
9	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	1.4	5
10	A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system. <i>IDCases</i> , 2021, 23, e01059.	0.4	0
11	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
12	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	0.9	5
13	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
14	A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. <i>Acta Hepatologica Japonica</i> , 2021, 62, 136-143.	0.0	0
15	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.3	2
16	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	1.7	8
17	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.0	0
18	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	3.5	23

#	ARTICLE	IF	CITATIONS
19	Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1517-1524.	0.4	0
20	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
21	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.3	1
22	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	1.7	29
23	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20
24	Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. <i>Medicine (United States)</i> , 2021, 100, e27576.	0.4	8
25	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	2.3	16
26	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	1.4	10
27	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	4.2	27
28	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
29	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	0.9	8
30	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	1.8	0
31	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	1.3	37
32	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
33	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.4	3
34	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
35	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
36	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81.	0.9	44
38	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.4	6
39	Levodopa Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	2.0	43
40	A case of primary hepatic leiomyosarcoma. <i>Acta Hepatologica Japonica</i> , 2019, 60, 358-365.	0.0	1
41	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
42	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28
43	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
44	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.2	4
45	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13
46	Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 0, , .	4.2	3